ArticleNature communications2024

Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial.

Liang Dong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.